| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910711197203321 |
|
|
Autore |
Barkley John <1945-> |
|
|
Titolo |
Selection of microcomputer systems / / John Barkley, Dennis Gilbert, Al Hankinson |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Gaithersburg, MD : , : U.S. Dept. of Commerce, National Institute of Standards and Technology, , 1984 |
|
|
|
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Collana |
|
NBS special publication ; ; 500-112 |
|
|
|
|
|
|
Altri autori (Persone) |
|
BarkleyJohn |
GilbertDennis |
HankinsonAl |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
1984. |
Contributed record: Metadata reviewed, not verified. Some fields updated by batch processes. |
Title from PDF title page. |
|
|
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910960031503321 |
|
|
Titolo |
Immunization safety review : influenza vaccines and neurological complications / / Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention ; Kathleen Stratton ... [et al.], editors, Institute of Medicine of the National Academies |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Washington, D.C., : National Academies Press, c2004 |
|
|
|
|
|
|
|
ISBN |
|
9780309527813 |
9786610176717 |
9781280176715 |
1280176717 |
9780309527811 |
0309527813 |
|
|
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (190 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Influenza vaccines - Side effects |
Nervous system - Diseases - Immunological aspects |
Immunization - Complications |
Vaccination - Complications |
Influenza Vaccines - adverse effects |
Infant |
Vaccination - adverse effects |
Nervous System Diseases - etiology |
Immunization Schedule |
Immune System Diseases - etiology |
Safety |
United States |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Bibliographic Level Mode of Issuance: Monograph |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
FrontMatter -- Reviewers -- Foreword -- Acknowledgments -- Contents -- Executive Summary -- Immunization Safety Review: Influenza Vaccines and Neurological Complications -- THE CHARGE TO |
|
|
|
|
|
|
|
|
|
|
|
THE COMMITTEE -- THE STUDY PROCESS -- THE FRAMEWORK FOR SCIENTIFIC ASSESSMENT -- UNDER REVIEW: INFLUENZA VACCINES AND NEUROLOGICAL COMPLICATIONS -- SCIENTIFIC ASSESSMENT -- SIGNIFICANCE ASSESSMENT -- RECOMMENDATIONS FOR PUBLIC HEALTH RESPONSE -- SUMMARY -- REFERENCES -- Appendixes -- Appendix A Committee Recommendations and Conclusions from Previous Reports -- Appendix B Public Meeting Agenda March 13, 2003 -- Appendix C Chronology of Important Events Regarding Vaccine Safety -- Appendix D Acronyms. |
|
|
|
|
|
|
Sommario/riassunto |
|
Infection with the influenza virus can have a serious effect on the health of people of all ages, although it is particularly worrisome for infants, the elderly, and people with underlying heart or lung problems. A vaccine exists (the oeflu shot) that can greatly decrease the impact of influenza. Because the strains of virus that are expected to cause serious illness and death are slightly different every year, the vaccine is also slightly different every year and it must be given every year, unlike other vaccines. The Immunization Safety Review committee reviewed the data on influenza vaccine and neurological conditions and concluded that the evidence favored rejection of a causal relationship between influenza vaccines and exacerbation of multiple sclerosis. For the other neurological conditions studied, the committee concluded the evidence about the effects of influenza vaccine is inadequate to accept or reject a causal relationship. The committee also reviewed theories on how the influenza vaccine could damage the nervous system. The evidence was at most weak that the vaccine could act in humans in ways that could lead to these neurological problems. |
|
|
|
|
|
|
|
| |